Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer

Michael Li; Jordan S Sack; Phoenix Bell; Osama E Rahma; Amitabh Srivastava; Shilpa Grover; Stephen D Zucker

doi:10.1001/jamaoncol.2021.4342

Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer

JAMA Oncol. 2021 Nov 1;7(11):1711-1714. doi: 10.1001/jamaoncol.2021.4342.

Authors

Michael Li^{1

2}, Jordan S Sack^{1

2}, Phoenix Bell^{2

3}, Osama E Rahma^{2

4}, Amitabh Srivastava^{2

3}, Shilpa Grover^{1

2}, Stephen D Zucker^{1

2}

Affiliations

¹ Division of Gastroenterology, Hepatology, and Endoscopy, Brigham & Women's Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Abstract

This cohort study examines the association of liver biopsy with management and outcomes of high-grade immune checkpoint inhibitor hepatitis.

MeSH terms

Biopsy
Hepatitis* / pathology
Humans
Immune Checkpoint Inhibitors
Neoplasms* / complications
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors